当资本开始为亏损买单：一场重构科技估值体系的深度博弈 一、政策破壁：亏损IPO背后的制度嬗变 2025年6月30日，科创板单日受理5家企业IPO，募资总额150亿元。这场看似寻常的资本动作，实则暗藏中国科技产业估值逻辑的重构密码： 亏损企业占比40%：摩尔线程（三年亏50亿）、沐曦股份（年亏14亿）闯关成功 研发投入成新"硬通货"： → 摩尔线程研发费率309%（2024年） → 沐曦股份营收3年暴增4074%（芯片流片驱动） 上市标准颠覆性变革：两家企业选择"市值+营收"新规（放弃盈利要求），印证证监会**"科创板八条"** 落地 政策深意：上海证券交易所内部人士透露，此次批量受理标志着 "技术变现周期容忍度" 正式纳入上市审核体系，为国产替代攻坚战打开资本输血通道。 摩尔线程： 二、硬科技突围的三重军备竞赛 1、技术攻坚：GPU国产化的"双雄路径" 维度 摩尔线程 沐曦股份 技术锚点 全功能GPU架构 7nm高性能计算GPU 破局场景 AI数字孪生（车企订单超5亿） 超算中心（签约国家实验室） 致命短板 制造依赖台积电 软件生态薄弱 沐曦MXN系列GPU实测算力达英伟达A100的82% 2、资本输血：研发 ...

小鹏汽车于北京时间2025年5月21日港股盘后、美股盘前发布了 2024 年一 季度财报。一季度财报表现都在预期之中，但二季度指引是呈现边际改善的，从实际表 现来看： 1）卖车毛利率仍然站上了低双位数，环比继续改善： 虽然本季度卖车单价还在下滑（主要低价小车Mona M03占比提高+清老款库存降价），但卖车毛利率因为 M03和P7+的热销带来的规模效应释放，仍然站上了低双位数10.5%的水平，环比继续提升0.5个百分点，也要略超市场10%的预期。 2）二季度销量指引符合预期： 二季度销量指引10.2-10.8万辆，隐含5/6月平均月销3.4万-3.7万辆，相比4月实际销量3.5万辆基本算是持平， 主要由于大产品周期在 三季度才能开启，二季度这样的销量指引也还可以。 3）收入预期隐含的卖车单价在环比回升： 收入预期隐含的卖车单价15.8万元，还继续环比回升0.5万元，仍然是呈现边际改善趋势，主要由于车型结构中更高价的 改款G6&G9占比的回升。 ① 新品周期非常强劲： 从小鹏2025年的产品周期来看，二季度末还有Mona M03智驾版本及中型SUV上市，预计开始放量都要集中在三季度，同时三季度及之后还有4款车型 ...

Group 1: Financial Performance - The company's revenue for 2024 reached 98,355.45 million, a year-on-year increase of 10.42% [2] - Net profit attributable to shareholders was 1,365.17 million, up 119.02% year-on-year, with the parent company's net profit at 5,635.84 million, increasing by 838.39% [2] - In Q1 2025, revenue was 28,268.07 million, showing a growth of 36.23% year-on-year, while net profit rose to 1,453.85 million, up 26.13% [2] Group 2: Profitability and Margins - The gross margin for 2024 was 47.67%, an increase of 0.66 percentage points compared to 2023 [3] - The company plans to enhance gross margins through continuous improvement in production processes and cost reduction [3] Group 3: Product Performance - Sales revenue from contrast agents reached 58,804.95 million in 2024, a growth of 9.87% year-on-year [3] - Sales of antidiabetic products grew by 33.24% year-on-year, attributed to successful bidding and subsequent contracts [4] Group 4: Research and Development - R&D expenses for 2024 were 6,923.81 million, a decrease of 43.40% compared to the previous year, due to a more stable phase in R&D and improved efficiency [5] - The company has 12 projects under review and 23 new R&D projects initiated [5] Group 5: Subsidiary Developments - The acquisition of Tianyuan Pharmaceutical increased the number of traditional Chinese medicine products to 59, with a focus on promoting unique products [8] - The construction of the production base for Luzhibao Pharmaceutical is ongoing, with trial production expected to start within the year [7] Group 6: Investor Relations and Governance - The total number of shareholders decreased by 7.37% by the end of Q1 2025, indicating a shift towards attracting more quality investors [10] - The company emphasizes a stable and scientific dividend policy to ensure sustainable returns to shareholders [10] Group 7: Debt Management - The company has sufficient funds to repay the principal and interest of convertible bonds due next year, ensuring no repayment risk [11]